Primary human hepatocytes-laden scaffolds for the treatment of acute liver failure

• Published in: Biomaterials advances 2023-10, Vol.153, p.213576-213576, Article 213576
• Main Authors: Rodriguez-Fernandez, Julio, Garcia-Legler, Emma, Villanueva-Badenas, Estela, Donato, M Teresa, Gomez-Ribelles, José Luis, Salmeron-Sanchez, Manuel, Gallego-Ferrer, Gloria, Tolosa, Laia
• Format: Article
• Language: English
• ISSN: 2772-9508; 2772-9508
• DOI: 10.1016/j.bioadv.2023.213576

Cell-based liver therapies based on retrieving and steadying failed metabolic function(s) for acute and chronic diseases could be a valuable substitute for liver transplants, even though they are limited by the low engraftment capability and reduced functional quality of primary human hepatocytes (PHH). In this paper we propose the use of gelatin-hyaluronic acid (Gel-HA) scaffolds seeded with PHH for the treatment of liver failure. We first optimized the composition using Gel-HA hydrogels, looking for the mechanical properties closer to the human liver and determining HepG2 cells functionality. Gel-HA scaffolds with interconnected porosity (pore size 102 μm) were prepared and used for PHH culture and evaluation of key hepatic functions. PHH cultured in Gel-HA scaffolds exhibited increased albumin and urea secretion and metabolic capacity (CYP and UGT activity levels) compared to standard monolayer cultures. The transplant of the scaffold containing PHH led to an improvement in liver function (transaminase levels, necrosis) and ameliorated damage in a mouse model of acetaminophen (APAP)-induced liver failure. The study provided a mechanistic understanding of APAP-induced liver injury and the impact of transplantation by analyzing cytokine production and oxidative stress induction to find suitable biomarkers of cell therapy effectiveness.